Allianz Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Allianz Asset Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-29,750	Closed	-$328K	–	2547
2016 Q1	$328K	Sell	29,750 -48,252	-62%	-$479K	﹤0.01%	2334
2015 Q4	$1.13M	Buy	78,002 +20,475	+36%	+$319K	﹤0.01%	1931
2015 Q3	$938K	Hold	57,527	–	–	﹤0.01%	1860
2015 Q2	$1.22M	Buy	57,527 +35,863	+166%	+$643K	﹤0.01%	1881
2015 Q1	$390K	Buy	+21,664	New	+$339K	﹤0.01%	2049

Other funds holding AVDL

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

FPC

Falcon Point Capital San Francisco, California $11.9M AUM 55.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Allianz Asset Management's AVDL Position: Q2 2016 in Review

Allianz Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q2 2016, closing a stake of 29,750 shares — an estimated $328K sold.

Allianz Asset Management first reported a position in AVDL in Q1 2015 and held it in 5 quarters. The position peaked at $1.22M in Q2 2015. 84 funds tracked by Wall St. Rank hold AVDL as of Q2 2016.

Allianz Asset Management reported no remaining Avadel Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Allianz Asset Management sold 29,750 Avadel Pharmaceuticals shares in Q2 2016, an estimated $328K.
Allianz Asset Management first reported a position in Avadel Pharmaceuticals in Q1 2015 and held it in 5 quarters.
Allianz Asset Management's Avadel Pharmaceuticals position peaked at $1.22M in Q2 2015.
84 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2016.

Based on Allianz Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.